Biotech, cancer, Drugs
Cell Therapeutics, Spectrum Form Joint Venture
Gregory T. Huang 11/26/08
Seattle-based Cell Therapeutics announced it has teamed up with Spectrum Pharmaceuticals of Irvine, CA, to create a 50-50 joint venture, RIT Oncology, to commercialize and develop the cancer drug Zevalin. The drug for non-Hodgkin’s lymphoma, which Xconomy has written about extensively, will be marketed in the U.S.
Gregory T. Huang is the Editor of Xconomy Seattle. You can e-mail him at gthuang@xconomy.com or call 206-624-2249.

11/27/08 8:44 pm
[...] to commercialize and develop the cancer drug Zevalin. The drug for non-Hodgkin’s … http://www.xconomy.com/seattle/2008/11/26/cell-therapeutics-spectrum-form-joint-venture/ « Monster Worldwide in joint venture with News Ltd. Unitech plans sale of assets to raise [...]